dr. neelapu on primary results of the zuma-1 trial in nhl
Published 7 years ago • 527 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
2:24
dr. neelapu on axi-cel in the zuma-1 trial for refractory aggressive non-hodgkin lymphoma
-
2:02
dr. neelapu on updated zuma-1 findings in non-hodgkin lymphoma
-
1:34
dr. neelapu on interim results of the phase ii zuma-1 study in dlbcl
-
0:55
dr. locke discusses the impact of the zuma-1 trial in nhl
-
0:46
key takeaway from 2-year follow-up data of zuma-1 trial in large b-cell lymphoma
-
2:03
long-term follow-up results from the zuma-1 trial in non-hodgkin lymphoma
-
2:00
long-term follow-up results of the zuma-1 trial of anti-cd19 car t-cells for non-hodgkin lymphoma
-
1:18
dr. neelapu on the safety profile of kte-c19 in patients with lymphoma
-
6:19
trial results on upadacitinib for the treatment of ra | roy fleischmann
-
5:31
kymriah® (tisagenlecleucel) mechanism of action in b-cell all and dlbcl
-
8:30
nih director: pfizer vaccine trial results ‘absolutely astounding’
-
1:43
dr. neelapu on third-line car t-cell therapy in large b-cell lymphoma
-
6:03
clinical data for axi-cel in lymphoma
-
1:23
dr. locke on the zuma-i trial of kte-c19
-
6:45
anticipation of zuma-7 results
-
6:37
initial results of zuma-3 trial ‘highly encouraging’ for relapsed, refractory leukemia
-
2:05
dr. roboz on impact of ctl019 in all
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
1:26
dr. hutchings on the aim of the echelon-1 study in hodgkin lymphoma
-
8:07
phase 1/2 study results of liposomal irinotecan and folfox in pancreatic cancer
-
0:39
dr. flinn on fda approval of tisagenlecleucel in dlbcl
-
2:21
primary results from the apollo study